Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
January 28, 2023 at 15:00 PM EST
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion, HutchMed will also pay royalties on net sales.
